𝔖 Bobbio Scriptorium
✦   LIBER   ✦

O6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course

✍ Scribed by Takao Watanabe; Yoichi Katayama; Chiaki Komine; Atsuo Yoshino; Akiyoshi Ogino; Takashi Ohta; Takao Fukushima

Publisher
John Wiley and Sons
Year
2004
Tongue
French
Weight
111 KB
Volume
113
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Epigenetic silencing of O 6 -methylguanine-DNA methyltransferase (MGMT) by promoter methylation can confer cancer cells with an increased sensitivity to alkylating chemotherapeutic agents and a higher susceptibility to TP53 transition mutations. The aim of our study was to assess the correlation of promoter methylation of the MGMT gene with TP53 mutations and the clinical characteristics of malignant astrocytomas. We analyzed the MGMT promoter methylation and TP53 mutations in 45 malignant astrocytomas (16 anaplastic astrocytomas and 29 glioblastomas multiforme) treated prospectively with 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-2(2-chloroethyl)-3-nitrosourea, interferon-␤ and radiation therapy, and evaluated their clinical usefulness. MGMT promoter methylation was found in 17 (38%) of the 45 newly diagnosed malignant astrocytomas. A clear trend existed between MGMT methylation and G:C to A:T transition mutations of TP53 (p ‫؍‬ 0.0596). Patients with MGMT-methylated tumors displayed a greater chance of responding to adjuvant therapy as compared with those with MGMT-unmethylated tumors (p ‫؍‬ 0.0393). TP53 mutation was not significantly associated with the clinical response (p ‫؍‬ 0.1310). While neither MGMT methylation nor TP53 mutation had a significant effect on prognosis of the whole population, the presence of MGMT methylation emerged as a significant predictor of a longer survival when exclusively analyzing 29 patients with glioblastomas multiforme. These findings highlight the importance of MGMT methylation as a specific predictive factor for responsiveness to nitrosourea chemotherapy.

📜 SIMILAR VOLUMES

Inactivation of the DNA repair gene O6-m
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relationship to aflatoxin B1-DNA adducts and p53 mutation in hepatocellular carcinoma
✍ Yu-Jing Zhang; Yu Chen; Habibul Ahsan; Ruth M. Lunn; Po-Huang Lee; Chien-Jen Che 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 237 KB 👁 1 views

## Abstract O^6^‐methylguanine‐DNA methyltransferase (MGMT) is a repair protein that specifically removes promutagenic alkyl groups from the O^6^ position of guanine in DNA. __MGMT__ is transcriptionally silenced by promoter hypermethylation in several human cancers. Methylation‐specific PCR (MSP)

DNA repair gene O6-methylguanine-DNA met
DNA repair gene O6-methylguanine-DNA methyltransferase: Promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors
✍ Dong Yin; Dong Xie; Wolf-Karsten Hofmann; Wenxuan Zhang; Kamlesh Asotra; Rex Won 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 220 KB

## Abstract The DNA repair enzyme O^6^‐methylguanine‐DNA methyltransferase (MGMT) removes alkylating adducts from the O^6^ position of guanine and protects cells from cytotoxic and mutagenic effects. Expression of __MGMT__ is decreased in some cancers, which may be the result of methylation of CpG